

Peer Review File

Article information: <https://dx.doi.org/10.21037/tlcr-23-273>

Reviewer A

This is a brilliantly written editorial on the updated results of the ADAURA trial looking at the clinical impact of adjuvant osimertinib in resected EGFRm NSCLC. The editorial is very comprehensive, the authors discuss important aspects in depth, such as optimal stage selection for adjuvant osimertinib, financial issues of using osimertinib for several years in the adjuvant setting as well as a potential negative impact on patients quality of life.

Comment 1: The authors should check all abbreviations and make sure they are spelled out at their first mentioning in the text, e.g. MRD.

Reply 1: Thank you so much for your review and the positive comments. We have checked all abbreviations and made sure they are spelled out accordingly.

Changes in Text:

Page 2: “immune checkpoint inhibitors targeting immune checkpoints T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein (PD-L1), and programmed cell death protein 1 (PD-1)”

Page 7: Circulating tumor DNA (ctDNA)

Page 8: minimal residual disease (MRD)

Reviewer B

The editorial is correctly written and keeps a balance with the knowledge and experience of adjuvant therapies in early resected NSCLC, as well as in early resected EGFR mutant NSCLC patients revisiting the benefit of adjuvant osimertinib. More specifically, it comments on the updated follow-up of the ADAURA study.

By and large it's a satisfactory editorial and I endorse its publication.

Reply 1: Thank you so much for your review of our manuscript and endorsing its publication.